Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine
Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal condition marked by chronic bowel pain or discomfort, as well as changes in abdominal motility. Despite its worldwide prevalence and clinical impact, the cause of IBS is unknown. Inflammation could play a fundamental role in...
Enregistré dans:
Auteurs principaux: | Sahar M. El‑Haggar, Sahar K. Hegazy, Sherief M. Abd-Elsalam, Mostafa M. Bahaa |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Elsevier
2022
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/4ee74657a09b4c18aa2c8a8fc9d5b97d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Effects of pentoxifylline on canine platelet aggregation
par: John M. Thomason, et autres
Publié: (2021) -
The role of visceral hypersensitivity in the pathogenesis of irritable bowel syndrome
par: Alina A. Makarova, et autres
Publié: (2021) -
Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm
par: Wiktoria Feret, et autres
Publié: (2021) -
Phosphodiesterase-4 Inhibition in Psoriasis
par: Milakovic M, et autres
Publié: (2021) -
Pentoxifylline therapy for patients with type 2 leprosy reactions: erythema nodosum leprosum in steroid-dependent cases
par: Khairuddin Djawad
Publié: (2021)